nnz-2591
Peptideexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started May 31, 2020 (NCT04379869)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
C=CC[C@@]12CCCN1C(=O)CNC2=O- Mol. weight
- 194.23 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802144 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07281079 | Phase 3 | Nov 12, 2025 | Neuren Pharmaceuticals Limited |
| NCT05879614 | Phase 2 | Sep 1, 2023 | Neuren Pharmaceuticals, Neuren Pharmaceuticals Limited |
| NCT05011851 | Phase 2 | Oct 1, 2021 | Neuren Pharmaceuticals, Neuren Pharmaceuticals Limited |
| NCT05025241 | Phase 2 | Oct 1, 2021 | Neuren Pharmaceuticals, Neuren Pharmaceuticals Limited |
| NCT05025332 | Phase 2 | Oct 1, 2021 | Neuren Pharmaceuticals, Neuren Pharmaceuticals Limited |
| NCT04379869 | Phase 1 | May 31, 2020 | Linear Clinical Research, Neuren Pharmaceuticals, Neuren Pharmaceuticals Limited |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neuren Pharmaceuticals Limited | For profit | 6 | 6 | 3 | 2020 |
| Neuren Pharmaceuticals | For profit | 5 | 0 | 2 | 2020 |
| Linear Clinical Research | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1